Accelerated Approval Of Lilly’s Alzheimer’s Drug Could Last About 15 Months, CEO Says

 
• By Brenda Sandburg

Lilly expects results from donanemab ongoing confirmatory trial in 2023, while Biogen has nine years to finish its postmarket study. CEO David Ricks discusses impact of aducanumab approval backlash, pricing and national coverage decision at STAT summit.

Alzheimer's research
Lilly expects to complete confirmatory trial to support accelerated approval of its Alzheimer's disease drug in 2023 • Source: Alamy

More from Clinical Trials

More from R&D